 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || lumateperone deuterated (ITI-1284 ODT-SL) - Intra / Cellular Therapies
Enrollment change, Trial completion date, Trial primary completion date: PET Study to Evaluate Brain Receptor Occupancy, Safety and Pharmacokinetics of ITI-1284 in Healthy Subjects (clinicaltrials.gov) - Jan 28, 2025
P1, N=30, Recruiting, Sponsor: Intra-Cellular Therapies, Inc.
N=12 --> 30 | Trial completion date: Mar 2025 --> Sep 2025 | Trial primary completion date: Mar 2025 --> Sep 2025
- || lumateperone deuterated (ITI-1284 ODT-SL) - Intra / Cellular Therapies
Trial completion date, Trial primary completion date: ITI-1284-301: Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder (clinicaltrials.gov) - Nov 22, 2024
P2, N=705, Recruiting, Sponsor: Intra-Cellular Therapies, Inc.
N=12 --> 30 | Trial completion date: Mar 2025 --> Sep 2025 | Trial primary completion date: Mar 2025 --> Sep 2025 Trial completion date: Jan 2027 --> Jun 2027 | Trial primary completion date: Dec 2026 --> Jun 2027
- ||||| lumateperone deuterated (ITI-1284 ODT-SL) - Intra / Cellular Therapies
New P2 trial: ITI-1284-101: A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia (clinicaltrials.gov) - Oct 20, 2024
P2, N=320, Recruiting, Sponsor: Intra-Cellular Therapies, Inc.
- ||||| lumateperone deuterated (ITI-1284 ODT-SL) - Intra / Cellular Therapies
New P2 trial: A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease (clinicaltrials.gov) - Aug 6, 2024
P2, N=370, Recruiting, Sponsor: Intra-Cellular Therapies, Inc.
- ||||| lumateperone deuterated (ITI-1284 ODT-SL) - Intra / Cellular Therapies
New P2 trial: ITI-1284-301: Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder (clinicaltrials.gov) - Jun 28, 2024
P2, N=705, Recruiting, Sponsor: Intra-Cellular Therapies, Inc.
- || lumateperone deuterated (ITI-1284 ODT-SL) - Intra / Cellular Therapies
Enrollment open: PET Study to Evaluate Brain Receptor Occupancy, Safety and Pharmacokinetics of ITI-1284 in Healthy Subjects (clinicaltrials.gov) - May 3, 2024
P1, N=12, Recruiting, Sponsor: Intra-Cellular Therapies, Inc.
Trial completion date: Jan 2027 --> Jun 2027 | Trial primary completion date: Dec 2026 --> Jun 2027 Not yet recruiting --> Recruiting
- || lumateperone deuterated (ITI-1284 ODT-SL) - Intra / Cellular Therapies
New P1 trial: PET Study to Evaluate Brain Receptor Occupancy, Safety and Pharmacokinetics of ITI-1284 in Healthy Subjects (clinicaltrials.gov) - Mar 6, 2024
P1, N=12, Not yet recruiting, Sponsor: Intra-Cellular Therapies, Inc.